Citations 2
Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology
Loren, Alison W. , Bolaños‐Meade, Javier , Brammer, Jonathan E. , Cowden, Meredith , Stasi, Antonio Di , El‐Jawahri, Areej , Elmariah, Hany , Gundabolu, Krishna , Gutman, Jonathan A. , Ho, Vincent T. , Hoeg, Rasmus T. , Horwitz, Mitchell E. , Jamy, Omer , Dabaja, Mohamed Kharfan, Lee, Lauren , Luszcak, Christina, Magenau, John, Martin, Thomas , Mittal, Varun , Moreira, Jonathan , Muffly, Lori , Nakamura, Ryotaro , Nawas, Mariam, Ninos, Cameron , Oliai, Caspian , Pidala, Joseph A. , Randolph, Brion, Tessier, Jeffrey, Topal, Jeffrey , Varshavsky‐Yanovsky, Asya, Jones, Frankie, Stehman, Katie, Elmariah, Hany , Jamy, Omer , Muffly, Lori , Mielcarek, Marco B. , Kassim, Adetola A , Logan, Aaron C , Nawas, Mariam T. , Nieto, Yago , Oliai, Caspian H , Papanicolaou, Genovefa A. , Schroeder, Mark A. , Tzachanis, Dimitrios
Journal of the National Comprehensive Cancer Network | October 9, 2025 | Volume: 23 | Issue: 10 | Pages: No page available
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hematopoietic Cell Transplantation (HCT) provide expert, multidisciplinary recommendations for autologous and allogeneic HCT based on current evidence. The NCCN Guidelines focus on pretransplant recipient evaluation, hematopoietic cell mobilization, conditioning, and the diagnosis and management of graft-versus-host disease (GVHD), a common complication of allogeneic HCT that is associated with significant morbidity. This selection from the NCCN Guidelines for HCT focuses on the diagnosis, workup, and management of acute and chronic GVHD, as well as important supportive care considerations.
NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022
Saad, Ayman , Loren, Alison W. , Bolaños‐Meade, Javier , Chen, George , Couriel, Daniel R. , Stasi, Antonio Di , El‐Jawahri, Areej , Elmariah, Hany , Gundabolu, Krishna , Gutman, Jonathan A. , Ho, Vincent T. , Hoeg, Rasmus T. , Horwitz, Mitchell E. , Hsu, Joe L. , Dabaja, Mohamed Kharfan, Magenau, John, Martin, Thomas , Moreira, Jonathan , Nakamura, Ryotaro , Ninos, Cameron , Oliai, Caspian , Patel, Seema M., Randolph, Brion, Tzachanis, Dimitrios , Varshavsky‐Yanovsky, Asya, Vusirikala, Madhuri , Algieri, Frankie, Pluchino, Lenora A. , Kharfan Dabaja, Mohamed, Saad, Ayman , Elmariah, Hany , Farag, Sherif Shafik , Kassim, Adetola A , Mielcarek, Marco B. , Nieto, Yago , Oliai, Caspian H , Schroeder, Mark A.
Journal of the National Comprehensive Cancer Network | February 15, 2023 | Volume: 21 | Issue: 2 | Pages: 108-115
The NCCN Guidelines for Hematopoietic Cell Transplantation (HCT) provide an evidence- and consensus-based approach for the use of autologous and allogeneic HCT in the management of malignant diseases in adult patients. HCT is a potentially curative treatment option for patients with certain types of malignancies; however, recurrent malignancy and transplant-related complications often limit the long-term survival of HCT recipients. The purpose of these guidelines is to provide guidance regarding aspects of HCT, including pretransplant recipient evaluation, hematopoietic cell mobilization, and treatment of graft-versus-host disease—a major complication of allogeneic HCT—to enable the patient and clinician to assess management options in the context of an individual patient’s condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for HCT, including the incorporation of a newly developed section on the Principles of Conditioning for HCT.